Press Releases

Filter: Year:

Compugen Reports Third Quarter 2019 Results

Preliminary Phase 1 clinical data presented at SITC 2019 demonstrate COM701 is well-tolerated with initial signals of anti-tumor activity

Nov 11, 2019
READ MORE

Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe

Added to previously granted U.S. patent protecting the use of COM902 for T cell activation in cancer patients

Nov 06, 2019
READ MORE

Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019

Data support potential clinical use as a cancer immunotherapy treatment in various combinations with COM701 and PD-1 inhibitors

Nov 05, 2019
READ MORE

Compugen Announces FDA Clearance of IND Application for COM902

Phase 1 clinical study in patients with advanced malignancies expected to begin in early 2020

Nov 04, 2019
READ MORE

Compugen to Present Data from Ongoing COM701 Phase 1 Clinical Trial at SITC 2019

Management will host its third quarter 2019 conference call on Monday, November 11, 2019 to provide a corporate update and review the Company’s poster presentations from SITC

Oct 02, 2019
READ MORE

Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients with Advanced Solid Tumors

Study based on well-tolerated doses with no reported DLTs of COM701 identified in monotherapy dose escalation arm of Phase 1 study

May 20, 2019
READ MORE

Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, its Lead Immuno-Oncology Product Candidate

Composition of matter patents expand intellectual property position beyond previously granted therapeutic use

Mar 12, 2019
READ MORE

Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium

Completion of enrollment of both monotherapy and dual combination dose escalation arms expected in 2019

Mar 01, 2019
READ MORE

Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy

Data published in Cancer Immunology Research indicate monotherapy and combination opportunities for COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG

Jan 22, 2019
READ MORE

Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial

Phase 1 study will assess COM701 both as a single agent and in combination with an anti-PD 1 antibody in patients with advanced solid tumors

Sep 07, 2018
READ MORE

Compugen Reports Second Quarter 2018 Results

Preparations for first patient dosing on track to take place in early fall

Aug 01, 2018
READ MORE

Compugen Welcomes FDA Clearance of Bayer’s IND Application for BAY 1905254

First-in-class therapeutic antibody targets ILDR2, a novel immune checkpoint discovered by Compugen

Jul 02, 2018
READ MORE

Compugen Announces FDA Clearance of IND Application for COM701, a First-in-Class Immuno-Oncology Therapeutic Antibody

A Phase 1 trial in patients with advanced solid tumors is to be conducted at multiple centers in the United States

Jul 02, 2018
READ MORE

Compugen Announces Exclusive License Agreement with MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products

Compugen will receive $10 million upfront, and is eligible for milestone payments and royalties on any products developed under the license

Apr 02, 2018
READ MORE

Compugen Reports Fourth Quarter and Full Year 2017 Results

Phase 1 Trial for COM701 Expected to Start in 2018

Feb 21, 2018
READ MORE

Compugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and its Use for the Treatment of Autoimmune Diseases in Two Back-to-Back Papers in The Journal of Immunology

ILDR2 forms the basis of ILDR2-Fc fusion protein, also known as CGEN-15001, Compugen’s product candidate for the treatment of autoimmune diseases

Feb 06, 2018
READ MORE

Compugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid Tumors

Data Further Strengthens Compugen’s Rationale for Clinical Development Plan and Biomarker Strategy for COM701

Jan 18, 2018
READ MORE

Compugen Reports Third Quarter 2017 Results

Phase I Study for COM701 Expected to Start in 2018

Nov 07, 2017
READ MORE

Compugen to Initiate Manufacturing of COM902, its Lead anti-TIGIT Monoclonal Antibody

COM902 IND anticipated in 2019 to allow clinical testing of combination therapies with COM701

Nov 06, 2017
READ MORE

Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month

Two poster presentations will present new COM701 and COM902 data

Oct 26, 2017
READ MORE

A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy

Supportive data generated as part of collaboration with the Johns Hopkins

Oct 09, 2017
READ MORE

Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month

Presentation will include new data on CGEN-15032, a novel target for cancer immunotherapy

Aug 07, 2017
READ MORE

Compugen Welcomes Paul Sekhri as its New Chairman of the Board

Appointment to take effect October 2, 2017

Aug 02, 2017
READ MORE

Compugen Reports Second Quarter 2017 Results

IND application for COM701 therapeutic antibody candidate for immuno-oncology expected to be filed towards the end of the first quarter of 2018

Aug 02, 2017
read more

Compugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology

Current Agreement to continue based on CGEN-15001T

Jul 26, 2017
READ MORE

Compugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product Candidate

Patent issued by USPTO under pilot program in support of the White House Cancer Moonshot program

Jul 25, 2017
READ MORE

Compugen Presents at ASCO COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models

Clinical advisory meeting held in preparation for COM701 clinical studies anticipated to begin next year

Jun 05, 2017
READ MORE

Compugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program

Strong clinical rationale for combination of COM701 and COM902 as cancer immunotherapies in addition to monotherapy use

Mar 28, 2017
READ MORE

Compugen to Present CGEN-15001 Autoimmune Product Candidate at Upcoming Conferences

CGEN-15001 Restores Immune Tolerance and Provides Potential Paradigm Shift in Standard of Care for Multiple Autoimmune Diseases

Mar 22, 2017
READ MORE

Compugen Announces Addition of Prof. Miriam Merad to Its Scientific Advisory Board

Prof. Merad is a distinguished leader in myeloid biology for the development of novel cancer immunotherapies

Mar 08, 2017
READ MORE

Compugen’s CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity

New data shows restoration of antigen-specific immune tolerance and re-establishment of immune homeostasis

Jan 04, 2017
READ MORE

Compugen Immune Checkpoint Program Demonstrates Potential for Development of New Cancer Immunotherapy Treatments

New preclinical results for CGEN-15029 presented in late-breaking session at Annual Meeting of the Society for Immunotherapy of Cancer

Nov 11, 2016
READ MORE

Compugen Ltd. Reports 3rd Quarter 2016 Financial Results

Quarterly conference call will be held on November 16, 2016

Nov 07, 2016
READ MORE

Compugen to Host R&D Day on December 7, 2016 in New York

Event to focus on the Company’s immuno-oncology programs

Nov 03, 2016
READ MORE

Compugen Third Quarter Financial Statements to be Released November 7, 2016

Third quarter conference call postponed to November 16 to allow discussion of new CGEN-15029 data to be presented at the Annual Meeting of the Society for Immunotherapy of Cancer

Oct 10, 2016
READ MORE

Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month

Presentation will include new data on CGEN-15029, a Compugen-discovered novel immune checkpoint target, including functional characterization and antibody blockade

Oct 07, 2016
READ MORE

Compugen Discloses Development of Enhanced LINKS Platform Utilized for the Discovery of Myeloid Targets for Cancer Immunotherapy

Myeloid target candidates predicted in silico using enhanced LINKS platform are now being experimentally validated

Aug 30, 2016
READ MORE

Compugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer

Compugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer

Apr 18, 2016
READ MORE

Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew Pardoll Appointed Director at Compugen USA, Inc.

Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew Pardoll Appointed Director at Compugen USA, Inc.

Apr 07, 2016
READ MORE

Compugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program

Multiple blocking antibodies discovered for Compugen novel immune checkpoint target candidate for treatment of cancer

Feb 29, 2016
READ MORE

Compugen Presents Translational Study Results Supporting CGEN-15001 for the Treatment of Rheumatoid Arthritis

Results of research collaboration with Prof. Iain B. McInnes from Glasgow University presented at the American College of Rheumatology Annual Meeting

Nov 09, 2015
READ MORE

Compugen Discloses New Results Supporting CGEN-15052 as Novel Immune Checkpoint Target Candidate for Treatment of Cancer

Data presented at the Inaugural International Cancer Immunotherapy Conference in New York City

Sep 16, 2015
READ MORE

Compugen to Disclose Novel Cancer Immunotherapy Target Candidate and Comprehensive Target Characterization Infrastructure at Today’s Analyst and Investor Day

CGEN-15029 target candidate is one of Compugen’s five highest priority cancer immunotherapy target programs

Jun 08, 2015
READ MORE

Compugen to Hold Analyst and Investor Day in New York

A live webcast of the presentations will be available via the Company’s website

May 27, 2015
READ MORE

Compugen Obtains Rights to Use Biological Systems and Materials from the US National Institutes of Health

Additional capabilities anticipated to enhance research and development of Compugen’s immuno-oncology programs

Apr 14, 2015
READ MORE

Compugen Announces Planned Relocation of Headquarters to Larger Facilities

New facilities double available space for corporate offices and research and discovery in Israel

Mar 19, 2015
READ MORE

Compugen to Present at Two Oncology Conferences in March

Presentations include experimental data demonstrating potential of Compugen-discovered novel immune checkpoints as targets for cancer immunotherapy

Mar 02, 2015
READ MORE

Compugen Expands and Strengthens Business Development Team

Felix Karim, PhD, joins Company as Vice President Corporate & Business Development

Feb 23, 2015
READ MORE

Compugen Presents New Results Supporting CGEN-15049 as Potential Cancer Immunotherapy Target

Data presented at the Keystone Symposia on Tumor Immunology

Feb 09, 2015
READ MORE

Compugen Discloses Initial Experimental Results for Predicted Antibody Drug Conjugate Targets

Pipeline Program for oncology to be further expanded and diversified with addition of ADC therapeutic programs to ongoing immuno-oncology programs

Jan 05, 2015
READ MORE

Compugen Ltd. Reports 2nd Quarter 2014 Financial Results

Oncology arm of Pipeline Program expanded to include three different approaches for antibody-based cancer therapy

Aug 06, 2014
READ MORE

Compugen Ltd. Reports First Quarter 2014 Results

Implementing expansion and acceleration campaign for Pipeline Program

May 19, 2014
READ MORE

Compugen Ltd. Reports Fourth Quarter and Calendar 2013 Results

Company discloses key 2014 corporate objectives

Feb 11, 2014
READ MORE
MORE EVENTS
Banner